Board approves Q1 FY27 results; revenue declines over 57 percent YoY

Revenue declinedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹30.40

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-2.9% vs market

Pharmaceuticals & Biotechnology peers, median of 172sector · industry level-0.4%-2.4% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8+0.1-2.9-0.4-2.4

Next day

-3.0+0.5-3.5-0.0-2.9

-2.9-0.1-2.8-0.8-2.2

+0.3+0.4-0.1-0.6+0.9

+0.0+0.7-0.7-0.9+0.9

—+0.9—-0.6—

-0.6+1.1-1.7-0.9+0.3

15d

-1.7+1.6-3.3+1.2-2.9

-0.5-0.7+0.2+0.4-0.9

+7.2-3.2+10.4-4.6+11.8

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved standalone unaudited Q1 FY27 results (quarter ended 30 Jun 2026). Revenue from operations fell to Rs 3.80 lakh from Rs 9 lakh YoY, a drop of about 58 percent. Profit stood at Rs 1.46 lakh versus Rs 2.47 lakh in Q1 FY26. Quarter on quarter, the company swung from a loss of Rs 81,745 to a profit. EPS was Rs 0.05 versus Rs 0.08 YoY. Statutory auditor Andros and Co issued an unmodified limited review report.

Likely market impact

Weak Q1 with sharp YoY revenue drop, though the company returned to profit sequentially. Very small scale of operations remains a concern.